Anlotinib in Combination With PD1 With Gemcitabine Plus(+)Cisplatin for Unresectable or Metastatic Biliary Tract Cancer
To evaluate the efficacy and safety of Anlotinib Hydrochloride in Combination With PD1 With Gemcitabine Plus(+)Cisplatin Compared With Gemcitabine +Cisplatin as First-line Chemotherapy for Unresectable or Metastatic Biliary Tract Cancer
Biliary Tract Cancer
DRUG: Anlotinib Hydrochloride in Combination With PD1 With Gemcitabine Plus(+)Cisplatin|DRUG: Gemcitabine Plus(+)Cisplatin
12 months OS rate, The definition of 12-months OS rate is the percentage of patients who had NOT has an event before or at 12 months, 360 days
Overall Survival (OS), OS is calculated from diagnosis to death or last follow-up time, up to 24 months after enrollment or study close|Progress free survival (PFS), PFS is defined as the time from the date of treatment to the first date of disease progression or death from any cause, up to 24 months after enrollment or study close|Objective response rate(ORR), Number of participants with partial response or complete response treating by anloitnib according to RESIST criteria v1.1., up to 24 months after enrollment or study close|Incidence of Treatment-Emergent 3/4 Adverse Events, Number and percentage of participants with Adverse Events (any Grade and Grade 3/4)., up to 24 months after enrollment or study close
Anlotinib is a multi-target receptor tyrosine kinase inhibitor in domestic research and development. It can inhibit the angiogenesis related kinase, such as VEGFR, FGFR, PDGFR, and c-Kit kinase.It is a randomized, controlled, multicenter phase II clinical trial conducted in China, and plan to recruit 80 patients who were primarily diagnosed with unresectable or metastatic biliary tract cancer who have not received previous systemic treatment.To evaluate the efficacy and safety of Anlotinib Hydrochloride in Combination With PD1 With Gemcitabine Plus(+)Cisplatin Compared With Gemcitabine +Cisplatin as First-line Chemotherapy for Unresectable or Metastatic Biliary Tract Cancer.